Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases

• Published in: Cellular immunology Vol. 362; p. 104300
• Main Authors: Zhang, Jilu, Hodges, Alan, Chen, Shu-Hsia, Pan, Ping-Ying
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.04.2021
• Subjects: Adoptive Transfer - methods; Autoimmune disease; Autoimmune Diseases - immunology; Autoimmunity - immunology; Cellular therapy; Humans; Immune Tolerance - immunology; Immunosuppressive Agents - pharmacology; Immunotherapy - methods; Myeloid Cells - immunology; Myeloid Cells - transplantation; Myeloid-derived suppressor cell; Myeloid-Derived Suppressor Cells - immunology; Myeloid-Derived Suppressor Cells - transplantation; Transplantation; Transplants - immunology; Autoimmune disease; Transplantation; Cellular therapy; Myeloid-derived suppressor cell
• ISSN: 0008-8749; 1090-2163
• DOI: 10.1016/j.cellimm.2021.104300

•MDSC cell therapy represents a new paradigm in the treatment of immunopathology.•Preclinical success in treatment of transplant rejection, GVHD and autoimmune disease.•Heterogenous results highlight need to tightly control parameters of MDSC therapy. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells, which have been characterized for their immunosuppressive capacity through multiple mechanisms. These cells have been extensively studied in the field of tumor immunity. Emerging evidence has highlighted its essential role in maintaining immune tolerance in transplantation and autoimmunity. Because of their robust immune inhibitory activities, there has been growing interest in MDSC-based cellular therapy. Various pre-clinical studies have demonstrated that the adoptive transfer of MDCS represented a promising therapeutic strategy for immune-related disorders. In this review, we summarize relevant studies of MDSC-based cell therapy in transplantation and autoimmune diseases and discuss the challenges and future directions for clinical application of MDSC-based cell therapy.